Syntis Bio Clinches $38M Series A to Revolutionize Oral Therapies for Obesity and Metabolic Health

Syntis Bio, a Boston-headquartered clinical-stage biopharmaceutical company, has successfully raised $38 million in a recent funding round, setting the stage for the next phase of its breakthrough innovations in oral therapy. Known for its pioneering approach that harnesses the small intestine’s unique biology, Syntis Bio is dedicated to delivering accessible, effective, and sustainable healthcare solutions across a broad spectrum—from rare genetic disorders to the most prevalent conditions worldwide. The infusion of capital will primarily fuel the advancement of its robust pipeline of oral therapies, with a particular focus on its lead program, SYNT-101. This once-daily oral pill for the treatment of obesity has been ingeniously engineered to mimic the effects of gastric bypass surgery, offering a non-invasive alternative for patients who struggle with weight management. At the heart of SYNT-101 is the company’s proprietary SYNT™ technology, which creates a safe, transient polymer coating in the duodenum to help regulate nutrient uptake while enhancing enzyme efficacy and drug absorption throughout the gut for up to 24 hours. With this funding, Syntis Bio plans not only to drive forward the clinical development of SYNT-101 but also to explore additional applications of its innovative platform to improve metabolic control, digestion, and overall drug delivery. This strategic investment underscores the growing confidence in Syntis Bio’s ability to transform treatment paradigms by targeting the small intestine—a critical nexus for metabolism and digestion—thereby paving the way for revolutionary advancements in both obesity management and broader healthcare challenges.